Interestingly, in MDD subjects, peripheral FKBP51 reduction is a marker for successful AD therapeutic outcome because FKBP51 levels are diminished in AD responders but not non-responders(Cattaneo et al., 2013). Here, FKBP5 is linked to major depressive disorder.